About this Journal Submit a Manuscript Table of Contents
Thrombosis
Volume 2012 (2012), Article ID 560513, 6 pages
http://dx.doi.org/10.1155/2012/560513
Research Article

Reversible Crystallization of Argatroban after Subcutaneous Application in Pigs

1Laboratorio de Hemostasia y Genetica Vascular, Centro de Bioquimica y Biofisica, Instituto Venezolano de Investigaciones Cientificas (IVIC), Caracas 1020, Venezuela
2University Hospital Jena, Friedrich Schiller University Jena, Erlanger Allee 101, 07747 Jena, Germany

Received 2 May 2012; Accepted 17 July 2012

Academic Editor: Graham F. Pineo

Copyright © 2012 Mercedes Lopez and Goetz Nowak. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. I. Weitz, “Low-molecular-weight heparins,” The New England Journal of Medicine, vol. 337, no. 10, pp. 688–698, 1997. View at Publisher · View at Google Scholar · View at Scopus
  2. T. E. Warkentin, “An overview of the heparin-induced thrombocytopenia syndrome,” Seminars in Thrombosis and Hemostasis, vol. 30, no. 3, pp. 273–283, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. R. E. Cronin and R. F. Reilly, “Unfractionated heparin for hemodialysis: still the best option,” Seminars in Dialysis, vol. 23, no. 5, pp. 510–515, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Di Nisio, S. Middeldorp, and H. R. Büller, “Direct thrombin inhibitors,” The New England Journal of Medicine, vol. 353, no. 10, pp. 1028–1040, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Greinacher and T. E. Warkentin, “The direct thrombin inhibitor hirudin,” Thrombosis and Haemostasis, vol. 99, no. 5, pp. 819–829, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. B. E. Lewis, D. E. Wallis, S. D. Berkowitz et al., “Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia,” Circulation, vol. 103, no. 14, pp. 1838–1843, 2001. View at Scopus
  7. K. McKeage and G. L. Plosker, “Argatroban,” Drugs, vol. 61, no. 4, pp. 515–522, 2001. View at Scopus
  8. C. Lee and J. Ansell, “Direct thrombin inhibitors,” British Journal of Clinical Pharmacology, vol. 72, pp. 581–592, 2011.
  9. S. Okamoto, A. Hijikata, R. Kikumoto et al., “Potent inhibition of thrombin by the newly synthesized arginine derivative No. 805. The importance of stereo-structure of its hydrophobic carboxamide portion,” Biochemical and Biophysical Research Communications, vol. 101, no. 2, pp. 440–446, 1981. View at Scopus
  10. M. J. Hursting, K. L. Alford, J. C. P. Becker et al., “Novastan (brand of argatroban): a small-molecule, direct thrombin inhibitor,” Seminars in Thrombosis and Hemostasis, vol. 23, no. 6, pp. 503–516, 1997. View at Scopus
  11. S. Kathiresan, J. Shiomura, and I. K. Jang, “Argatroban,” Journal of Thrombosis and Thrombolysis, vol. 13, no. 1, pp. 41–47, 2002. View at Publisher · View at Google Scholar · View at Scopus
  12. S. K. Swan and M. J. Hursting, “The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction,” Pharmacotherapy, vol. 20, no. 3, pp. 318–329, 2000. View at Scopus
  13. S. K. Swan, J. V. S. Peter, L. J. Lambrecht, and M. J. Hursting, “Comparison of anticoagulant effects and safety of argatroban and heparin in healthy subjects,” Pharmacotherapy, vol. 20, no. 7, pp. 756–770, 2000. View at Scopus
  14. M. Lopez and G. Nowak, “Influence of renal and hepatic failure on the pharmacokinetics of argatroban: an experimental study in rats,” Seminars in Thrombosis and Hemostasis, vol. 34, no. 1, pp. 103–107, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. P. C. A. Kam, N. Kaur, and C. L. Thong, “Direct thrombin inhibitors: pharmacology and clinical relevance,” Anaesthesia, vol. 60, no. 6, pp. 565–574, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. G. Nowak and E. Bucha, “Quantitative determination of hirudin in blood and body fluids,” Seminars in Thrombosis and Hemostasis, vol. 22, no. 2, pp. 197–202, 1996. View at Scopus
  17. U. Lange, G. Nowak, and E. Bucha, “Ecarin chromogenic assay— a new method for quantitative determination of direct thrombin inhibitors like hirudin,” Pathophysiology of Haemostasis and Thrombosis, vol. 33, no. 4, pp. 184–191, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Rowland and T. Tozer, Clinical pharmacokinetics. Concepts and applications, Lippincott Williams Wilkins, 3rd edition, 1995.
  19. J. Hirsh and R. Raschke, “Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy,” Chest, vol. 126, no. 3, supplement, pp. 188S–203S, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. J. Hirsh, K. A. Bauer, M. B. Donati, et al., “Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,” Chest, vol. 133, supplement, no. 6, pp. 141S–159S, 2008. View at Scopus
  21. F. Schiele, A. Vuillemenot, T. Mouhat et al., “Subcutaneous recombinant hirudin in the treatment of deep venous thrombosis: a pharmacokinetic study,” Archives des Maladies du Coeur et des Vaisseaux, vol. 88, no. 3, pp. 329–335, 1995. View at Scopus
  22. G. Lefèvre, M. Duval, S. Gauron et al., “Effect of renal impairment on the pharmacokinetics and pharmacodynamics of desirudin,” Clinical Pharmacology and Therapeutics, vol. 62, no. 1, pp. 50–59, 1997. View at Publisher · View at Google Scholar · View at Scopus
  23. J. Humphries, C. Lattimer, A. Smith et al., “High and constant plasma levels of tissue plasminogen activator and PEG- hirudin can be achieved by subcutaneous delivery,” Thrombosis Research, vol. 87, no. 1, pp. 123–129, 1997. View at Publisher · View at Google Scholar · View at Scopus
  24. H. U. Esslinger, S. Haas, R. Maurer, A. Lassmann, K. Dübbers, and H. Müller-Peltzer, “Pharmacodynamic and safety results of PEG-Hirudin in healthy volunteers,” Thrombosis and Haemostasis, vol. 77, no. 5, pp. 911–919, 1997. View at Scopus
  25. M. L. Brader, M. Sukumar, A. H. Pekar et al., “Hybrid insulin cocrystals for controlled release delivery,” Nature Biotechnology, vol. 20, no. 8, pp. 800–804, 2002. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Jen, K. Madörin, K. Vosbeck, T. Arvinte, and H. P. Merkle, “Transforming growth factor β-3 crystals as reservoirs for slow release of active TGF-β3,” Journal of Controlled Release, vol. 78, no. 1–3, pp. 25–34, 2002. View at Publisher · View at Google Scholar · View at Scopus
  27. P. J. MacMahon, S. J. Eustace, and E. C. Kavanagh, “Injectable corticosteroid and local anesthetic preparations: a review for radiologists,” Radiology, vol. 252, no. 3, pp. 647–661, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Tripodi, V. Chantarangkul, A. A. Arbini, M. Moia, and P. M. Mannucci, “Effects of hirudin on activated partial thromboplastin time determined with ten different reagents,” Thrombosis and Haemostasis, vol. 70, no. 2, pp. 286–288, 1993. View at Scopus
  29. R. C. Gosselin, W. E. Dager, J. H. King et al., “Effect of direct thrombin inhibitors, bivalirudin, lepirudin, and argatroban, on prothrombin time and INR values,” American Journal of Clinical Pathology, vol. 121, no. 4, pp. 593–599, 2004. View at Publisher · View at Google Scholar · View at Scopus